Podcast 6 Sep 2024
The power of tumor infiltrating lymphocytes to fight melanoma
Listen to our conversation with Brian Gastman, EVP of medical affairs at Iovance Biotherapeutics, about TILs and the company’s pipeline.
Melanoma
- Latest Posts
News and Trends 27 Aug 2024
Could microbiome drugs be the key to unlocking checkpoint inhibitors’ potential?
As Microbiotica announces phase 1 approval for two microbiome drugs we delve into their potential in oncology and beyond.
In Depth 16 Aug 2023
Can a vaccine be the solution to the surge in melanoma cases caused by the climate crisis?
Melanoma is the most serious type of skin cancer, and is primarily caused by too much exposure to ultraviolet (UV) light – in the U.K., around 85% of melanomas are thought to be caused by too much ultraviolet radiation. And, unfortunately, because of this, the surge in global temperatures caused by the climate crisis is […]
News and Trends 16 Feb 2023
Cytovation melanoma study under way
Cytovation ASA, a Norwegian clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class targeted tumor membrane immunotherapy, announces that the first patient has been dosed in its phase 2a study. The trial is investigating CyPep-1 monotherapy in patients with advanced melanoma refractory to checkpoint inhibitors (CPIs). The study is an expansion arm […]
News and Trends 1 Nov 2022
Proscia presents results on AI melanoma diagnostic predictions
Proscia has released study results on new artificial intelligence (AI) that predicts diagnostic agreement for melanoma, the deadliest form of skin cancer. The findings, presented at the European Conference on Computer Vision (ECCV) 2022, highlight the potential of the technology to improve diagnostic accuracy for melanoma and other diseases with low pathologist concordance. Conducted at […]
News and Trends 5 Oct 2022
OncoSec slashing staff numbers to prioritize pipeline
OncoSec Medical Incorporated is restructuring to prioritize development of its lead clinical candidate TAVO (TAVO-EP). TAVO is a plasmid encoding interleukin 12 (IL-12) delivered by intratumoral electroporation. Oncosec is reducing its staff by approximately 45% and prioritizing clinical pipeline activities to reduce operating expenses. The company and remaining employees will focus clinical activities in melanoma […]
ADVERTISEMENT
ADVERTISEMENT
Using the power of proteomics to predict immunotherapy responses in melanoma and beyond
Next-generation proteomics has a vital role to play in the search for new biomarkers of immunotherapy response. Recent studies in melanoma presented at the European Society for Medical Oncology (ESMO) Congress highlight how these insights have the potential to transform cancer care. The recent success of immunotherapies that manipulate the patient’s immune system to recognize […]
News and Trends 22 Sep 2022
Swiss scientists reduce resistance of dormant melanoma cells
Small-molecule targeted therapies revolutionized the treatment of metastatic melanoma, provided that the tumors carry the mutations to respond to these treatments. However, despite an initial response that can be seen in a majority of patients, most of them will undergo relapse even after sometimes spectacular initial responses. These relapses are due to “dormant” persistent cells, […]
News and Trends 6 Nov 2019
UK Biotech Launched to Target ‘Dark Antigens’ with Cancer Vaccines
The London-based startup Ervaxx has launched with a €15.8M Series A round to develop cancer vaccines and cell therapies that target ‘dark antigens’ — normally silent genes in the genome that are expressed in cancer cells. Ervaxx’s Series A round was funded by the transatlantic venture capital firm SV Health Investors, as well as an […]
News and Trends 3 Sep 2019
UK Biotech’s Personalized Immunotherapy gets €110M Series B Boost
The UK company Achilles Therapeutics has raised €110M (£100M) to test its personalized cancer cell immunotherapies in humans for the first time. The large Series B round will fund two phase I/IIa clinical trials of Achilles’ preclinical immunotherapy which are expected to start this year: one in non-small cell lung cancer and the other in […]
Startup Scout 5 Jul 2019
This Biotech Helps the Immune System to Infiltrate and Destroy Tumors
The Nice-based biotech company Yukin Therapeutics is developing drugs that can work together with checkpoint inhibitors to help the immune system smash tumors such as melanoma. Mission: To develop a drug that can change the tumor microenvironment to allow the immune system to infiltrate and destroy the tumor more effectively. This could give a big […]
Interview 24 Jul 2018
Meet the Dutch Scientists who Invented Keytruda, “The President’s Drug”
Known for curing US President Jimmy Carter’s cancer, Keytruda continues to benefit many other cancer patients. The inventors told us their story, from the drug’s early days to their current role as executives of the biotech unicorn Aduro. Since 2014, the cancer drug Keytruda, also known as pembrolizumab, continues to be widely sought after due […]
ADVERTISEMENT